1-[4-[2-Hydroxy-2-[4-hydroxy-3-(hydroxyMethyl)phenyl]ethoxy]-3-(hydroxyMethyl)phenyl]-2-[[6-(3-phenylbutoxy)hexyl]aMino]ethanol;4-O-[2-Hydroxy-2-[4-hydroxy-3-(hydroxyMethyl)phenyl]ethyl] SalMeterol;SalMeterol EP IMpurity D;Salmeterol Xinafoate BP Impurity D;Salmeterol Impurity 5（Salmeterol EP Impurity D ）;1,3-Benzenedimethanol, 4-[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethoxy]-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-;Salmeterol Impurity 5（EP Impurity D ）;Salmeterol EP Impurity D/ Salmeterol O-Alkyl Impurity
Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility
DMSO (Slightly), Methanol (Slightly)
form
Solid
pka
9.89±0.31(Predicted)
color
Orange to Red
Stability:
Very Hygroscopic
Safety Information
MSDS Information
SalMeterol EP IMpurity D Usage And Synthesis
Uses
4-O-[2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl] Salmeterol is an impurity of the β2-Adrenergic agonist Salmeterol (S090100).
Uses
4-O-[2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl] Salmeterol (Salmeterol EP Impurity D) is an impurity of the β2-Adrenergic agonist Salmeterol (S090100).
SalMeterol EP IMpurity D Preparation Products And Raw materials
